This site may require a log-in in the near future. We are constantly being swamped by AI agents. If they continue to take down the site, we will be changing to requiring logins to access any item.

🍽️ loxapine succinate,(prescription)

AI Engines For more Details: Perplexity  Kagi Labs  You 

  1. Schizophrenia:

    • Loxapine succinate is effective in managing the symptoms of schizophrenia, including hallucinations, delusions, disorganized thinking, and emotional disturbances. It helps to stabilize mood and reduce the severity and frequency of psychotic episodes.

  2. Other Psychotic Disorders:

    • Loxapine succinate may also be prescribed for other psychotic disorders such as schizoaffective disorder, bipolar disorder with psychotic features, and psychotic depression. It helps to alleviate symptoms of paranoia, agitation, and mood disturbances associated with these conditions.

  3. Acute Agitation:

    • Adasuve, a formulation of loxapine administered via inhalation, is specifically indicated for the rapid control of acute agitation associated with schizophrenia or bipolar disorder in adults. It provides a non-invasive and fast-acting option for managing acute episodes of agitation.

  4. Maintenance Therapy:

    • Loxapine succinate may be used as maintenance therapy to prevent relapse in individuals with schizophrenia or other psychotic disorders. It helps to stabilize symptoms over the long term and reduce the risk of recurrence of psychotic episodes.

  5. Off-Label Uses:

    • In some cases, loxapine succinate may be prescribed off-label for conditions such as agitation in dementia, severe anxiety, or mood disorders. However, the efficacy and safety of loxapine for these indications may vary, and its use should be carefully monitored by a healthcare provider.

  6. Side Effects:

    • Common side effects of loxapine succinate may include drowsiness, dizziness, dry mouth, constipation, blurred vision, weight gain, and extrapyramidal symptoms such as tremors, muscle stiffness, and tardive dyskinesia.
    • Rare but serious side effects may include neuroleptic malignant syndrome (NMS), which is a life-threatening condition characterized by fever, muscle rigidity, altered mental status, and autonomic dysfunction. Immediate medical attention is required if symptoms of NMS occur.

  7. Precautions:

    • Loxapine succinate should be used with caution in elderly patients, individuals with a history of cardiovascular disease, diabetes, or seizure disorders, and those at risk of developing NMS. Dosage adjustments may be necessary based on individual factors and medical history.
    • It is important to avoid alcohol and other central nervous system depressants while taking loxapine succinate, as they may increase the risk of sedation and respiratory depression.

  8. Monitoring:

    • Patients prescribed loxapine succinate should be regularly monitored by their healthcare provider for the emergence of side effects, changes in symptoms, and overall treatment response. Blood tests may be conducted to monitor liver function and metabolic parameters.
;

Check for interactions on Supp.AI   |   📚 PubMed Citations

⚗️ Compensation for antibiotic usage

Data Contradictions — Limits of Certainity

Impacted of loxapine succinate,(prescription) On Probiotics

Rank Probiotic Impact
genus Bifidobacterium Reduces
species Akkermansia muciniphila Reduces
species Bacteroides uniformis Reduces
species Bifidobacterium adolescentis Reduces
species Bifidobacterium longum Reduces
species Faecalibacterium prausnitzii Reduces
species Parabacteroides distasonis Reduces
subspecies Bifidobacterium longum subsp. infantis Reduces
subspecies Bifidobacterium longum subsp. longum Reduces

Bacteria Impacted by loxapine succinate,(prescription)

We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.

🧙?

📓 Direct Citations 👪👶 Indirect Citations Taxonomy Rank Effect
0 1 Akkermansiaceae family Decreases
0 1 Phocaeicola genus Decreases
0 1 Parabacteroides genus Decreases
0 1 Odoribacter genus Decreases
0 1 Bacteroides genus Decreases
0 1 Agathobacter genus Decreases
1 0 Akkermansia genus Decreases
0 1 Lachnospira genus Decreases
0 1 Lacrimispora genus Decreases
0 1 Segatella genus Decreases
0 1 Thomasclavelia genus Decreases
0 1 Eggerthella genus Decreases
0 1 Alistipes genus Decreases
0 1 Coprobacter genus Decreases
0 1 Dorea genus Decreases
0 1 Barnesiella genus Decreases
0 1 Clostridioides genus Decreases
0 1 Mediterraneibacter genus Decreases
0 1 Butyricimonas genus Decreases
0 1 Streptococcus genus Decreases
0 1 Bifidobacterium genus Decreases
0 1 Veillonella genus Decreases
0 1 Enterocloster genus Decreases
0 1 Clostridium genus Decreases
0 1 environmental samples no rank Decreases
0 1 unclassified Akkermansia no rank Decreases
0 1 Clostridium perfringens A no rank Decreases
0 1 Clostridium perfringens B no rank Decreases
0 1 Clostridium perfringens C no rank Decreases
0 1 Clostridium perfringens CPE no rank Decreases
0 1 Clostridium perfringens D no rank Decreases
0 1 Clostridium perfringens E no rank Decreases
1 0 Segatella copri species Decreases
1 0 Agathobacter rectalis species Decreases
1 0 Akkermansia muciniphila species Decreases
1 0 Bacteroides caccae species Decreases
1 0 Bacteroides fragilis species Decreases
1 0 Bacteroides ovatus species Decreases
1 0 Bacteroides thetaiotaomicron species Decreases
1 0 Bacteroides uniformis species Decreases
1 0 Lachnospira eligens species Decreases
1 0 Lacrimispora saccharolytica species Decreases
1 0 Odoribacter splanchnicus species Decreases
1 0 Parabacteroides distasonis species Decreases
1 0 Parabacteroides merdae species Decreases
1 0 Phocaeicola vulgatus species Decreases
1 0 Thomasclavelia ramosa species Decreases
1 0 Eggerthella lenta species Decreases
1 0 [Ruminococcus] torques species Decreases
0 1 Bacteroides humanifaecis species Decreases
1 0 Dorea formicigenerans species Decreases
1 0 Clostridioides difficile species Decreases
0 1 Segatella bryantii species Decreases
0 1 Bacteroides sp. CACC 737 species Decreases
0 1 uncultured Alistipes sp. species Decreases
0 1 Bacteroides sp. D2 species Decreases
0 1 Bacteroides luhongzhouii species Decreases
0 1 Alistipes ihumii species Decreases
0 1 Eggerthella guodeyinii species Decreases
1 0 Streptococcus parasanguinis species Decreases
0 1 Bacteroides sp. A1C1 species Decreases
0 1 Bacteroides sp. M10 species Decreases
1 0 Bifidobacterium adolescentis species Decreases
0 1 Alistipes sp. dk3624 species Decreases
0 1 Bacteroides sp. HF-162 species Decreases
0 1 Leyella stercorea species Decreases
0 1 Alistipes finegoldii species Decreases
0 1 Bacteroides sp. DH3716P species Decreases
0 1 Butyricimonas virosa species Decreases
1 0 Veillonella parvula species Decreases
0 1 Alistipes dispar species Decreases
0 1 Akkermansia glycaniphila species Decreases
0 1 Akkermansia massiliensis species Decreases
0 1 Candidatus Akkermansia intestinavium species Decreases
0 1 Alistipes megaguti species Decreases
0 1 Prevotella intermedia species Decreases
1 0 Bifidobacterium longum species Decreases
0 1 Streptococcus sp. HSISM1 species Decreases
0 1 Streptococcus sp. LPB0220 species Decreases
0 1 Alistipes communis species Decreases
0 1 Alistipes shahii species Decreases
0 1 Coprobacter fastidiosus species Decreases
0 1 Alistipes senegalensis species Decreases
0 1 Leyella lascolaii species Decreases
1 0 Enterocloster bolteae species Decreases
0 1 Alistipes indistinctus species Decreases
0 1 Bacteroides faecium species Decreases
0 1 Coprococcus catus species Decreases
0 1 Coprobacter secundus species Decreases
0 1 Barnesiella viscericola species Decreases
0 1 Alistipes onderdonkii species Decreases
0 1 Butyrivibrio crossotus species Decreases
0 1 Paraprevotella clara species Decreases
1 0 Mediterraneibacter gnavus species Decreases
0 1 Prevotella bivia species Decreases
0 1 Wujia chipingensis species Decreases
0 1 Roseburia rectibacter species Decreases
0 1 Butyricimonas faecalis species Decreases
0 1 Bacteroides xylanisolvens species Decreases
0 1 Faecalibacterium prausnitzii species Decreases
0 1 Blautia obeum species Decreases
0 1 Dorea longicatena species Decreases
0 1 Bacteroides caecimuris species Decreases
0 1 Coprococcus comes species Decreases
0 1 Parabacteroides johnsonii species Decreases
0 1 Pseudobutyrivibrio xylanivorans species Decreases
0 1 Wansuia hejianensis species Decreases
0 1 Eubacterium sp. MSJ-33 species Decreases
0 1 Ligilactobacillus ruminis species Decreases
0 1 Subdoligranulum variabile species Decreases
0 1 Simiaoa sunii species Decreases
0 1 Bacteroides nordii species Decreases
0 1 Prevotella dentalis species Decreases
0 1 Komagataeibacter oboediens species Decreases
0 1 Clostridium sp. M62/1 species Decreases
0 1 Faecalibacillus intestinalis species Decreases
1 0 Clostridium perfringens species Decreases
0 1 Bifidobacterium longum subsp. infantis subspecies Decreases
0 1 Bifidobacterium longum subsp. longum subspecies Decreases
0 1 Bifidobacterium longum subsp. suillum subspecies Decreases
0 1 Bifidobacterium longum subsp. suis subspecies Decreases

Impact of loxapine succinate,(prescription) on Conditions from US National Library of Medicine

A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.

We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive   X|increases + Y|decrease = Negative.

Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.

Condition Positive Impact Negative Impact Benefit Ratio Impact
Abdominal Aortic Aneurysm 0.6 0.6
Acne 0.1 -0.1
ADHD 3.3 0.2 15.5
Age-Related Macular Degeneration and Glaucoma 0.1 0.5 -4
Allergic Rhinitis (Hay Fever) 1.4 1.1 0.27
Allergies 2.8 2.6 0.08
Allergy to milk products 1.1 1.2 -0.09
Alopecia (Hair Loss) 0.8 0.1 7
Alzheimer's disease 5.2 4.4 0.18
Amyotrophic lateral sclerosis (ALS) Motor Neuron 3.1 0.6 4.17
Ankylosing spondylitis 3 1 2
Anorexia Nervosa 0.8 2.7 -2.38
Antiphospholipid syndrome (APS) 0.7 0.1 6
Asthma 3.3 2 0.65
Atherosclerosis 1.4 1.1 0.27
Atrial fibrillation 3.1 2.4 0.29
Autism 6.8 7.6 -0.12
Autoimmune Disease 0.2 0.1 1
Barrett esophagus cancer 0.1 0.1 0
benign prostatic hyperplasia 0.5 -0.5
Biofilm 0.4 0.4
Bipolar Disorder 1.6 0.3 4.33
Brain Trauma 0.2 0.7 -2.5
Cancer (General) 0.6 1 -0.67
Carcinoma 2.3 1.9 0.21
Celiac Disease 2.3 3.1 -0.35
Cerebral Palsy 1.2 0.5 1.4
Chronic Fatigue Syndrome 3 4.8 -0.6
Chronic Kidney Disease 2.8 2 0.4
Chronic Lyme 0.2 0.5 -1.5
Chronic Obstructive Pulmonary Disease (COPD) 0.3 0.7 -1.33
Chronic Urticaria (Hives) 0.2 1.9 -8.5
Coagulation / Micro clot triggering bacteria 0.6 0.1 5
Cognitive Function 1.3 0.8 0.63
Colorectal Cancer 4.6 1.6 1.87
Constipation 1.5 1.5
Coronary artery disease 0.7 2.4 -2.43
COVID-19 7.8 9.9 -0.27
Crohn's Disease 5.6 5.2 0.08
Cushing's Syndrome (hypercortisolism) 1.1 -1.1
cystic fibrosis 0.7 -0.7
deep vein thrombosis 1 0.6 0.67
Denture Wearers Oral Shifts 0.2 0.2
Depression 7.8 5.7 0.37
Dermatomyositis 0.1 0.1 0
Eczema 0.4 1 -1.5
Endometriosis 1.5 1 0.5
Eosinophilic Esophagitis 0.2 -0.2
Epilepsy 2.2 2.7 -0.23
erectile dysfunction 0.5 0.2 1.5
Fibromyalgia 2.3 2 0.15
Functional constipation / chronic idiopathic constipation 4.4 3.6 0.22
gallstone disease (gsd) 1.5 0.8 0.88
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus 1.4 0.6 1.33
Generalized anxiety disorder 1.3 1.2 0.08
giant cell arteritis 0 0
Glioblastoma 0.1 -0.1
Gout 1.7 0.5 2.4
Graves' disease 1.1 1.2 -0.09
Gulf War Syndrome 0.1 2.3 -22
Halitosis 0.6 0.1 5
Hashimoto's thyroiditis 2.3 1.8 0.28
Heart Failure 2 1.3 0.54
hemorrhagic stroke 0.8 0.8
Hidradenitis Suppurativa 1 0.1 9
High Histamine/low DAO 0.1 0.2 -1
hypercholesterolemia (High Cholesterol) 0.5 0.6 -0.2
hyperglycemia 0.4 2.3 -4.75
Hyperlipidemia (High Blood Fats) 0.5 0.3 0.67
hypersomnia 0.1 -0.1
hypertension (High Blood Pressure 3.9 4.2 -0.08
Hypothyroidism 0.6 0.3 1
Hypoxia 1.8 1.8
IgA nephropathy (IgAN) 1.3 3.9 -2
Inflammatory Bowel Disease 5 6.3 -0.26
Insomnia 0.8 2.8 -2.5
Intelligence 1.1 0.7 0.57
Intracranial aneurysms 1.1 1.1
Irritable Bowel Syndrome 4.2 5.1 -0.21
ischemic stroke 1.5 1.2 0.25
Liver Cirrhosis 4 2.6 0.54
Long COVID 6.1 5.1 0.2
Low bone mineral density 0.1 0.5 -4
Lung Cancer 0.6 1.2 -1
Lymphoma 0.3 -0.3
Mast Cell Issues / mastitis 0.1 0.2 -1
ME/CFS with IBS 0.4 1.4 -2.5
ME/CFS without IBS 1 1.7 -0.7
membranous nephropathy 0.1 0.1
Menopause 1.1 0.4 1.75
Metabolic Syndrome 4.2 5.4 -0.29
Mood Disorders 7.7 5 0.54
multiple chemical sensitivity [MCS] 0.6 0.1 5
Multiple Sclerosis 3.9 4.9 -0.26
Multiple system atrophy (MSA) 1.3 0.1 12
myasthenia gravis 0.1 0.2 -1
neuropathic pain 0.2 2.6 -12
Neuropathy (all types) 0.7 1.3 -0.86
neuropsychiatric disorders (PANDAS, PANS) 0.6 0.6
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic 3.6 3.9 -0.08
NonCeliac Gluten Sensitivity 1.4 0.6 1.33
Obesity 6.3 5.2 0.21
obsessive-compulsive disorder 4.7 3.4 0.38
Osteoarthritis 1.9 1.2 0.58
Osteoporosis 0.8 1.4 -0.75
pancreatic cancer 0.6 0.1 5
Parkinson's Disease 5.6 4.9 0.14
Peanut Allergy 0.1 -0.1
Polycystic ovary syndrome 4 1.7 1.35
Postural orthostatic tachycardia syndrome 0 0.2 0
Premenstrual dysphoric disorder 0.1 0.5 -4
primary biliary cholangitis 0.3 0.7 -1.33
Primary sclerosing cholangitis 1.5 1.6 -0.07
Psoriasis 1.6 3.5 -1.19
rheumatoid arthritis (RA),Spondyloarthritis (SpA) 3.5 2.7 0.3
Rosacea 0.4 0.1 3
Schizophrenia 4.2 2 1.1
scoliosis 0.6 -0.6
Sjögren syndrome 2.2 2.8 -0.27
Sleep Apnea 0.2 0.8 -3
Slow gastric motility / Gastroparesis 0.6 0.1 5
Small Intestinal Bacterial Overgrowth (SIBO) 0.7 0.1 6
Stress / posttraumatic stress disorder 1.7 2.2 -0.29
Systemic Lupus Erythematosus 2.6 1.7 0.53
Tic Disorder 1.2 1.1 0.09
Tourette syndrome 0.7 0.5 0.4
Type 1 Diabetes 3.2 2.1 0.52
Type 2 Diabetes 5.9 5.3 0.11
Ulcerative colitis 3.9 6.8 -0.74
Unhealthy Ageing 3 2.6 0.15
Vitiligo 2.1 1.3 0.62

Explanations /Info /Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations.Please report any to us for correction.

Copyright 2016 - 2025 Lassesen Consulting, LLC[2007], DBA, Microbiome Prescription All rights served.   Permission to data scrap or reverse engineer is explicitly denied to all users.U.S.Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA   Use of data on this site is prohibited except under written license.There is no charge for individual personal use.Use for any commercial applications or research requires a written license.   Caveat emptor: Analysis and suggestions are based on modelling(and thus infererence ) based on studies.The data sources are usually given for those that wish to consider alternative inferences.theories and models.   Inventions /Methodologies on this site are Patent Pending.

Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not in strict compliance with Personal Health Information Laws. [216.73.216 ]